Gene expression profile as a prognostic factor in proliferative diseases of reproductory system

Malignant tumors of reproductive system are the most common malignancies in women. Fortunately modern screening methods allow diagnose breast, cervical, endometrial, est., cancers at initial stages. This progress led to decreased mortality rate in women population and simultaneously allows use less aggressive tactic in patient’s management. But on the other hand existing prognostic and predictive systems, such as TNM classification with extra factors depending on disease localization, that include 2 “classical” prognostic factors (tumor size, limph-node status, ER/PR receptors, est.), cannot provide needed prognostic capacity for individualized treatment course. According to this problem many modern methods remain underappreciated. Today specialists in clinics need new, more accurate prognostic models that help to individualize treatment course for every patient. Besides, the rate of therapy individualization is totally depends on a prognostic system accuracy. Gene expression profiling is one of the methods that allow to asses and quantificate the tumor portrait on the mRNA level. Gene expression changes in tumor tissue are described in many studies but there are only few gene expression prognostic systems that recommended for clinical use additionally to existing models. This review is devoted to gene expression changes in breast, cervical and endometrial cancers, and the role of gene expression profiling in clinic.